Response to Letter to the Editor on "Impact of the Surgical Approach for Neoadjuvantly Treated Gastroesophageal Junction Type II Tumors: A Multinational, High-Volume Center Retrospective Cohort Analysis"
- PMID: 39310347
- PMCID: PMC11415085
- DOI: 10.1097/AS9.0000000000000479
Response to Letter to the Editor on "Impact of the Surgical Approach for Neoadjuvantly Treated Gastroesophageal Junction Type II Tumors: A Multinational, High-Volume Center Retrospective Cohort Analysis"
Comment on
-
Impact of the Surgical Approach for Neoadjuvantly Treated Gastroesophageal Junction Type II Tumors: A Multinational, High-volume Center Retrospective Cohort Analysis.Ann Surg. 2023 Nov 1;278(5):683-691. doi: 10.1097/SLA.0000000000006011. Epub 2023 Jul 31. Ann Surg. 2023. PMID: 37522845
Similar articles
-
Comment on "Impact of the Surgical Approach for Neoadjuvantly Treated Gastroesophageal Junction Type II Tumors: A Multinational, High-Volume Center Retrospective Cohort Analysis".Ann Surg Open. 2024 May 22;5(2):e446. doi: 10.1097/AS9.0000000000000446. eCollection 2024 Jun. Ann Surg Open. 2024. PMID: 38911639 Free PMC article. No abstract available.
-
Impact of the Surgical Approach for Neoadjuvantly Treated Gastroesophageal Junction Type II Tumors: A Multinational, High-volume Center Retrospective Cohort Analysis.Ann Surg. 2023 Nov 1;278(5):683-691. doi: 10.1097/SLA.0000000000006011. Epub 2023 Jul 31. Ann Surg. 2023. PMID: 37522845
-
Optimal Treatment Strategies for cT2 Staged Adenocarcinoma of the Esophagus and the Gastroesophageal Junction: A Multinational, High-volume Center Retrospective Cohort Analysis.Ann Surg. 2024 Nov 1;280(5):799-807. doi: 10.1097/SLA.0000000000006478. Epub 2024 Aug 7. Ann Surg. 2024. PMID: 39109441
-
Evaluation of neoadjuvant immunotherapy in resectable gastric/gastroesophageal junction tumors: a meta-analysis and systematic review.Front Immunol. 2024 Jan 30;15:1339757. doi: 10.3389/fimmu.2024.1339757. eCollection 2024. Front Immunol. 2024. PMID: 38352873 Free PMC article.
-
Treatment results of adenocarcinoma of the gastroesophageal junction.Hepatogastroenterology. 2008 Mar-Apr;55(82-83):475-81. Hepatogastroenterology. 2008. PMID: 18613391 Review.
References
-
- Wirsik NM, Schmidt T, Nienhüser H, et al. . Impact of the surgical approach for neoadjuvantly treated gastroesophageal junction type II tumors: a multinational, high-volume center retrospective cohort analysis. Ann Surg. 2023;278:683–691. - PubMed
-
- Horvath B, Kloesel B, Todd MM, et al. . The evolution, current value, and future of the american society of anesthesiologists physical status classification system. Anesthesiology. 2021;135:904–919. - PubMed
-
- Torrens M, Fonseca F. Opioid use and misuse in Europe: COVID-19 new challenges? Eur Neuropsychopharmacol. 2022;54:67–69. - PubMed
-
- Shapiro J, van Lanschot JJB, Hulshof M, et al. . Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial. Lancet Oncol. 2015;16:1090–1098. - PubMed
Publication types
LinkOut - more resources
Full Text Sources